2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Pedro C. Barata, MD, MSc, discusses challenges associated with treating advanced urothelial carcinoma.
Pedro C. Barata, MD, MSc, an associate professor of Medicine in Hematology and Medical Oncology at the Tulane University School of Medicine, discusses challenges associated with treating advanced urothelial carcinoma.
The pace of updates in the treatment space for advanced and non-metastatic urothelial carcinoma is a challenge since it can be difficult to stay up to speed with all the latest advancements, Barata explains. Keeping community practitioners informed and aware of developing novel therapies can help more patients get access to the best agents for their disease, Barata adds.
The delay associated with the release of new data and the implementation of new agents in practice is concerning because some patients may not have access to the best-available care, Barata continues. As the space continues to evolve, keeping the community oncologists informed of the best available treatment options will be critical, Barata concludes.